Status:
UNKNOWN
Effectiveness of Hydroxychloroquine in Covid-19 Patients
Lead Sponsor:
Prof. Dr. Umar Farooq
Collaborating Sponsors:
Ayub Medical College, Abbottabad
Conditions:
COVID19
Eligibility:
All Genders
18-50 years
Phase:
PHASE3
Brief Summary
To find the effectiveness of hydroxychloroquine alone and adjuvant with azithromycin in mild to severe Covide-19 pneumonia patients admitted to Coronavirus cell/ward of Ayub Teaching hospital, Abbotta...
Detailed Description
Coronavirus (SARS-nCoV-2) is a member family coronaviridae, order Nidovirales. It is single-stranded, positive sense enveloped RNA discovered in early 1960s. Coronavirus pandemic put a lot of lives at...
Eligibility Criteria
Inclusion
- Confirmed cases of Covid-19 (all by RT-PCR from same laboratory)
- Mild to severe clinical presentation (identified at the time of admission to ward by National Early Warning Score NEWS-2; mild 0-4; severe 5-6)
Exclusion
- Covid-19 critically ill patients (NEWS-2 score \<7),
- Unable to take oral medication,
- Immunocompromised,
- Creatinine clearance (CCL) \< 30 ml/min,
- Aspartate transaminase (AST) or alanine transaminase (ALT) \> 5 times Upper limit of normal (ULN),
- d-dimer \> 2microgram per liter, or
- Known comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, COPD, cerebrovascular disorder, malignancy of any type, pregnancy,
- BMI less than 18
- Smoking history (one pack per day) for past six months
Key Trial Info
Start Date :
March 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 28 2020
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04328272
Start Date
March 28 2020
End Date
June 28 2020
Last Update
April 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ayub Teaching Institution
Abbottābād, K.p.k, Pakistan, 00532